Cancer, Cardiac Diseases, Cardiovascular Diseases, Vascular Diseases
Conditions
Brief summary
The aim of this observational study is to explore and analyze reports of cardiac or vascular adverse events linked to the administration of antineoplastic agents among patients diagnosed with tumors represented by advanced non-small cell lung cancer. The study leverages pharmacovigilance databases such as the World Health Organization (WHO) database (VigiBase), FDA Adverse Event Reporting System (FAERS), and others to gather individual safety case reports for analysis.
Detailed description
Concomitant antineoplastic drug therapy may produce serious adverse cardiac or vascular system events. In this study, reports of cardiovascular adverse drug events following treatment with antineoplastic drugs were investigated using the World Health Organization (WHO) personal safety case report database (VigiBase) and FDA Adverse Event Reporting System (FAERS).
Interventions
DRUGAntineoplastic Agents
small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics
Sponsors
The First Affiliated Hospital of Xinxiang Medical College
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024. 2. Adverse events reported were including the MedDRA terms: Cardiac disorders (SOC), Vascular disorders (SOC), Cardiac and vascular investigations (excl enzyme tests) (HLGT), Sudden death (PT), Sudden cardiac death (PT), Cardiac arrhythmias (HLGT), Cardiac disorder signs and symptoms (HLGT), Cardiac neoplasms (HLGT), Cardiac valve disorders (HLGT), Coronary artery disorders (HLGT), Endocardial disorders (HLGT), Heart failures (HLGT), Myocardial disorders (HLGT), Pericardial disorders (HLGT), Vascular disorders NEC(HLGT), Vascular inflammations(HLGT), Embolism and thrombosis(HLGT), Vascular hypertensive disorders(HLGT), Blood pressure disorders NEC(HLGT), Venous varices(HLGT), Arteriosclerosis, stenosis, vascular insufficiency and necrosis(HLGT), Aneurysms and artery dissections(HLGT). 3. Patients treated with antineoplastic agents (including small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics). 4. The number of reports corresponding to each drug or adverse event is at least three. 5. The primary indication is malignant tumors, specifically advanced non-small cell lung cancer.
Exclusion criteria
1. Any of the information in the baseline information such as gender, age, region, date of report is empty. 2. The severity level of the reported adverse event is empty. 3. Adverse events were reported in patients whose drug indications included cardiovascular disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardio-vascular toxicity of antineoplastic agents | Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024 | Identification and report of the cardio-vascular toxicity of antineoplastic agents. The research includes the report with MedDRA terms: SOC Cardiac Disorders, SOC Vascular Disorders, Cardiac and vascular investigations (excl enzyme tests) (HLGT), Skeletal and cardiac muscle analyses (HLT), Sudden death (PT). Drugs investigated are antineoplastic agents. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the association between cardiovascular toxicity due to antineoplastic agents and risk factors. | Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024 | Cardiovascular events are identified using MedDRA terms. Each cardiovascular event and risk factor will be assessed for potential over-reporting by calculating odds ratios. Factors evaluated will include, but are not limited to, cancer type and patient baseline characteristics (gender, age, country of reporting, etc.). Additionally, the year of reporting and other relevant variables will be considered. |
| Assess cardiovascular toxicity differences among antineoplastic agent classes and within the same class. | Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024 | The data were classified into different drug classes based on the Anatomical Therapeutic Chemical (ATC) classification system. This included small molecule kinase inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. The occurrence of major adverse events was identified using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. The differences in cardiovascular toxicity between drug classes were evaluated using disproportionality analysis (single drug vs. full database). To assess toxicity differences between drugs in the same class, for example, a comparison could be made between the cardiovascular toxicity of drugs such as erlotinib, afatinib, and osimertinib, which all belong to the category of EGFR tyrosine kinase inhibitors. Disproportionality analyses (single drug vs. other drugs in the same class) were employed in this regard. |
| Assessment of the severity of cardiovascular toxicity associated with antineoplastic agents | Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024 | Reports with fatal outcomes will be compared with reports without fatal outcomes. Odds ratio will be calculated to compare covariates that may be associated with an increased risk of death, including type of adverse cardiovascular event, type of cancer reported, age of the patient, gender, comorbidities, and antitumor monotherapy or combination therapy. |
| Causality assessment of reported cardiovascular events according to pharmacovigilance databases | Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024 | Disproportionality individual case data analysis between cardiovascular events and antineoplastic agents. |
| Description of the drug-drug interactions associated with adverse events. | Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024 | Describe cardiovascular adverse events reported when two or more drugs are taken concurrently or consecutively in patients with the same indication. |
| Description of the population of patients having a cardio-vascular adverse events | Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024 | The patient population with cardiovascular adverse events was described in terms of baseline information, including patient indication, age, sex, country of reporting origin, and clinical outcomes, among other factors. |
| Description of the duration of treatment when the toxicity happens (role of cumulative dose) | Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024 | The analysis includes analyzing the relationship between the duration of treatment and the occurrence of toxicity, taking into account the cumulative dose of the administered medication. |
Contacts
Primary ContactXiaohong Kang, PhD
Backup ContactZidong Ma, MS
Outcome results
None listed